ROS Responsive Nanoplatform with Two‐Photon AIE Imaging for Atherosclerosis Diagnosis and “Two‐Pronged” Therapy

Boxuan Ma,Hong Xu,Weihua Zhuang,Yanan Wang,Gaocan Li,Yunbing Wang
DOI: https://doi.org/10.1002/smll.202003253
IF: 13.3
2020-10-20
Small
Abstract:<p>Atherosclerosis, characterized by endothelial injury, progressive inflammation, and lipid deposition, can cause cardiovascular diseases. Although conventional anti‐inflammatory drugs reveal a certain amount of therapeutic effect, more reasonable design on plaque targeting, local anti‐inflammation, and lipid removal are still required for comprehensive atherosclerosis therapy. In this work, a theranostic nanoplatform is developed for atherosclerosis recognition and inhibition. A two‐photon aggregation‐induced emission (AIE) active fluorophore (TP) developed is linked to β‐cyclodextrin (CD) with a ROS responsive bond, which can carry prednisolone (Pred) in its entocoele via supramolecular interaction to build a diagnosis‐therapy compound two‐photon fluorophore‐cyclodextrin/prednisolone complexes (TPCDP). With TPCDP packaged by nanosized micelles based on a ROS sensitive copolymer poly (2‐methylthio ethanol methacrylate)‐poly (2‐methacryloyloxyethyl phosphorylcholine), the TPCDP@PMM can accumulate in atherosclerotic tissue through the damaged vascular endothelium. Activated by the local overexpressed ROS and rich lipid, the micelles are interrupted and TPCDP is further disintegrated with Pred release due to the relatively stronger interaction of lipid with CD, resulting in anti‐inflammatory activity and lipid removal for atherosclerosis inhibition. Besides, labeled with the TP, TPCDP@PMM indicates a distinct two‐photon AIE imaging on atherosclerosis recognition. The "two‐pronged" therapeutic effect and plaque location ability has been confirmed in vivo on ApoE<sup>−/−</sup> mice, holding TPCDP@PMM a great promise for atherosclerosis theranostics.</p>
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
What problem does this paper attempt to address?
The main objective of this paper is to develop a nano-theranostic platform for the diagnosis and treatment of atherosclerosis. Specifically, the research team designed a nano-platform (TPCDP@PMM) that responds to reactive oxygen species (ROS) and has two-photon aggregation-induced emission (AIE) imaging capabilities to achieve the identification of atherosclerosis and a "dual-pronged" treatment strategy. To achieve this goal, the researchers first synthesized a complex (TPCD) containing a two-photon AIE fluorescent molecule (TP) and β-cyclodextrin (CD), and loaded the anti-inflammatory drug prednisolone (Pred) into CD through supramolecular interactions to form TPCDP. Then, using a ROS-sensitive polymer (PMEMA-PMPC, PMM), they encapsulated TPCDP into nanoparticles (TPCDP@PMM). These nanoparticles can stably circulate in the blood and accumulate at atherosclerotic lesions through the damaged vascular endothelium. When these nanoparticles reach the inflammation site, the excessive ROS triggers the PMEMA chains to transition from hydrophobic to hydrophilic, causing the nanoparticles to disassemble and release TPCDP. After the ROS-sensitive linkers in TPCDP are broken, Pred is released to exert anti-inflammatory effects; simultaneously, CD interacts with the abundant lipids at the lesion site, promoting lipid clearance. Additionally, TP can produce a strong fluorescence signal under two-photon excitation, enabling high-resolution bioimaging, which aids in the identification of atherosclerotic plaques. In summary, this study aims to achieve precise diagnosis and effective treatment of atherosclerotic plaques by constructing the TPCDP@PMM nano-platform. This includes utilizing its two-photon AIE imaging capability for plaque identification and leveraging the anti-inflammatory effects of Pred and the lipid-clearing function of CD to inhibit plaque formation and progression.